Meeting
2021 ASCO Annual Meeting
Imaging HER2-positive metastatic esophagogastric cancer with 89Zr-trastuzumab PET and 18F-FDG PET.
Authors
Melissa Amy Lumish
Memorial Sloan Kettering Cancer Center, New York, NY
Melissa Amy Lumish , Steven Brad Maron , Viktoriya Paroder , Steven Philemond , Joseph A. O' Donoghue , Heiko Schöder , Jason Stuart Lewis , Yelena Y. Janjigian , Neeta Pandit-Taskar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02023996
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4068)
DOI
10.1200/JCO.2021.39.15_suppl.4068
Abstract #
4068
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab refractory esophagogastric (EG) cancer.
First Author: Yelena Yuriy Janjigian
Poster
2014 Gastrointestinal Cancers Symposium
A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer.
First Author: Yelena Yuriy Janjigian
Poster
2022 ASCO Annual Meeting
![The HERPET study: Imaging HER2 expression in breast cancer with the novel PET tracer [<sup>18</sup>F]GE-226, a first-in-patient study.](https://d201v5jt9ylckg.cloudfront.net/288/14358/211270/211270_A4766_poster_pv.jpg)
The HERPET study: Imaging HER2 expression in breast cancer with the novel PET tracer [18F]GE-226, a first-in-patient study.
First Author: Laura M. Kenny
Poster
2024 ASCO Gastrointestinal Cancers Symposium
HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind, multicenter phase 2 study.
First Author: Jin Li